María A. Gomis-Font

419 total citations
21 papers, 221 citations indexed

About

María A. Gomis-Font is a scholar working on Molecular Medicine, Pharmacology and Molecular Biology. According to data from OpenAlex, María A. Gomis-Font has authored 21 papers receiving a total of 221 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Medicine, 10 papers in Pharmacology and 7 papers in Molecular Biology. Recurrent topics in María A. Gomis-Font's work include Antibiotic Resistance in Bacteria (20 papers), Antibiotics Pharmacokinetics and Efficacy (10 papers) and Bacterial biofilms and quorum sensing (6 papers). María A. Gomis-Font is often cited by papers focused on Antibiotic Resistance in Bacteria (20 papers), Antibiotics Pharmacokinetics and Efficacy (10 papers) and Bacterial biofilms and quorum sensing (6 papers). María A. Gomis-Font collaborates with scholars based in Spain, United States and Australia. María A. Gomis-Font's co-authors include Antonio Oliver, Carla López-Causapé, Gabriel Cabot, Antonio Oliver, Pablo A. Fraile-Ribot, Xavier Mulet, Laura Zamorano, Bartolomé Moyá, Carlos Juan and Sara Cortés-Lara and has published in prestigious journals such as Nature Communications, Antimicrobial Agents and Chemotherapy and PLoS Pathogens.

In The Last Decade

María A. Gomis-Font

19 papers receiving 219 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
María A. Gomis-Font Spain	8	213	124	69	63	52	21	221
Veronika Wirth Australia	6	170 0.8×	139 1.1×	38 0.6×	29 0.5×	71 1.4×	7	229
Sara Cortés-Lara Spain	5	110 0.5×	61 0.5×	44 0.6×	34 0.5×	27 0.5×	10	142
Congrong Li China	10	96 0.5×	34 0.3×	55 0.8×	25 0.4×	62 1.2×	21	219
Evangelia Neou Greece	3	145 0.7×	93 0.8×	30 0.4×	29 0.5×	38 0.7×	4	177
Sergey Altunin Israel	3	158 0.7×	122 1.0×	13 0.2×	50 0.8×	71 1.4×	3	178
Trond Egil Ranheim Norway	6	127 0.6×	20 0.2×	87 1.3×	34 0.5×	70 1.3×	8	205
Artjohn Villafania United States	4	91 0.4×	71 0.6×	128 1.9×	46 0.7×	26 0.5×	6	222
Yael Dishon Benattar Israel	2	158 0.7×	122 1.0×	10 0.1×	50 0.8×	71 1.4×	2	170
Supriya Upadhyay India	7	165 0.8×	26 0.2×	71 1.0×	40 0.6×	19 0.4×	12	186
Abdullah Tarık Aslan Australia	7	89 0.4×	46 0.4×	21 0.3×	46 0.7×	44 0.8×	13	143

Countries citing papers authored by María A. Gomis-Font

Since Specialization

Citations

This map shows the geographic impact of María A. Gomis-Font's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María A. Gomis-Font with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María A. Gomis-Font more than expected).

Fields of papers citing papers by María A. Gomis-Font

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by María A. Gomis-Font. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María A. Gomis-Font. The network helps show where María A. Gomis-Font may publish in the future.

Co-authorship network of co-authors of María A. Gomis-Font

This figure shows the co-authorship network connecting the top 25 collaborators of María A. Gomis-Font. A scholar is included among the top collaborators of María A. Gomis-Font based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María A. Gomis-Font. María A. Gomis-Font is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gomis-Font, María A., Emilio Lence, Salud Rodríguez-Pallares, et al.. (2025). Functional and structural analyses of amino acid sequence variation in PDC β-lactamase reveal different mechanistic pathways toward cefiderocol resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 69(7). e0029225–e0029225. 3 indexed citations

Gomis-Font, María A., Daría Roca, Pedro Ribera, et al.. (2025). First nationwide survey on Pseudomonas aeruginosa in Bolivia: susceptibility profiles, resistome, and genomic epidemiology. Antimicrobial Agents and Chemotherapy. 69(12). e0116325–e0116325.

Gomis-Font, María A., Salud Rodríguez-Pallares, Alejandro Beceiro, et al.. (2025). Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 69(12). e0104825–e0104825.

Gomis-Font, María A., Carla López-Causapé, Jorge Arca-Suárez, et al.. (2025). Spanish nationwide survey of Pseudomonas aeruginosa cefiderocol susceptibility and resistance mechanisms. International Journal of Antimicrobial Agents. 66(4). 107563–107563. 2 indexed citations

Gomis-Font, María A., et al.. (2025). Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel β-lactams in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 69(4). e0194224–e0194224. 3 indexed citations

Hernando‐Amado, Sara, María A. Gomis-Font, José Ramón Valverde, Antonio Oliver, & José Luis Martínez. (2025). Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa. Nature Communications. 16(1). 3323–3323. 2 indexed citations

Oliver, Antonio, et al.. (2025). Emerging resistance mechanisms to newer β-lactams in Pseudomonas aeruginosa. Clinical Microbiology and Infection. 31(11). 1790–1796. 7 indexed citations

Cabot, Gabriel, et al.. (2024). Differential contribution of PBP occupancy and efflux on the effectiveness of β-lactams at their target site in clinical isolates of Neisseria gonorrhoeae. PLoS Pathogens. 20(12). e1012783–e1012783. 1 indexed citations

Rodríguez-Pallares, Salud, María A. Gomis-Font, Pablo A. Fraile-Ribot, et al.. (2024). Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 79(11). 3023–3028. 7 indexed citations

10.

Jordana‐Lluch, Elena, María A. Gomis-Font, Pablo A. Fraile-Ribot, et al.. (2024). Collateral susceptibility-guided alternation of ceftolozane/tazobactam with imipenem prevents resistance development in XDR Pseudomonas aeruginosa biofilms. Biofilm. 8. 100231–100231. 1 indexed citations

11.

Cortés-Lara, Sara, Ester del Barrio-Tofiño, María A. Gomis-Font, et al.. (2024). Monitoring of Pseudomonas aeruginosa mutational resistome dynamics using an enrichment panel for direct sequencing of clinical samples. EBioMedicine. 108. 105367–105367. 1 indexed citations

12.

Gomis-Font, María A., Carla López-Causapé, María Diez‐Aguilar, et al.. (2024). Mechanisms leading to in vivo ceftazidime/avibactam resistance development during treatment of GES-5-producing Pseudomonas aeruginosa infections. Antimicrobial Agents and Chemotherapy. 68(11). e0116424–e0116424. 2 indexed citations

13.

Roson-Calero, Natalia, Jonathan Lucas, María A. Gomis-Font, et al.. (2024). Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against Acinetobacter baumannii. Antibiotics. 13(12). 1147–1147. 1 indexed citations

14.

Agyeman, Akosua Adom, Carla López-Causapé, Kate E. Rogers, et al.. (2023). Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity. International Journal of Antimicrobial Agents. 62(3). 106887–106887. 10 indexed citations

15.

Gomis-Font, María A., et al.. (2023). In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 78(7). 1785–1794. 29 indexed citations

16.

Gomis-Font, María A., María Ángeles Clari, Carla López-Causapé, David Navarro, & Antonio Oliver. (2023). Emergence of cefiderocol resistance during ceftazidime/avibactam treatment caused by a large genomic deletion, including ampD and piuCD genes, in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 68(1). e0119223–e0119223. 14 indexed citations

17.

López-Causapé, Carla, María A. Gomis-Font, Xavier Mulet, et al.. (2022). Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clinical Microbiology and Infection. 29(4). 538.e7–538.e13. 23 indexed citations

18.

Gomis-Font, María A., Gabriel Cabot, Laura Zamorano, et al.. (2021). Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones. Journal of Antimicrobial Chemotherapy. 77(4). 957–968. 21 indexed citations

19.

Gomis-Font, María A., Cristina Pitart, Ester del Barrio-Tofiño, et al.. (2021). Emergence of Resistance to Novel Cephalosporin–β-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump. Antimicrobial Agents and Chemotherapy. 65(8). e0008921–e0008921. 39 indexed citations

20.

Gomis-Font, María A., Gabriel Cabot, Irina Sánchez-Diener, et al.. (2020). In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 75(9). 2508–2515. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact